Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 08, 2011
Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
The development of this second-generation test, which in court documents the company has referred to as OvaCheck 2, has potentially important implications for Correlogic in its ongoing licensing dispute and for the firm's eventual sale of its assets.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Court Grants Correlogic's Motion to Reject OvaCheck Licensing Agreements with Quest and LabCorp
October 8, 2010 / ProteoMonitor - Joining LabCorp, Quest Files Objection to Correlogic's Motion to Reject OvaCheck Licensing Agreements
September 3, 2010 / ProteoMonitor - LabCorp Counters Correlogic's Motion in Bankruptcy Case to Reject OvaCheck Licensing Agreements
August 6, 2010 / ProteoMonitor - Is Healthlinx Eyeing Purchase of Correlogic's Assets as Part of Move into US Cancer Dx Market?
October 14, 2011 / ProteoMonitor - Auction of Correlogic's Assets Pushed Back to Give Potential Buyers Time for Due Diligence
June 17, 2011 / ProteoMonitor